Skip to Content
Merck
All Photos(1)

Documents

I7901

Sigma-Aldrich

Monoclonal Anti-Interleukin-6 antibody produced in mouse

clone 6708.11, purified immunoglobulin, lyophilized powder

Synonym(s):

Anti-IL-6

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
51111800
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

6708.11, monoclonal

form

lyophilized powder

species reactivity

human

technique(s)

indirect ELISA: suitable
neutralization: suitable
western blot: suitable

isotype

IgG1

UniProt accession no.

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... IL6(3569)

General description

Interleukin-6 is a pleotropic cytokine involved in hematopoiesis, inflammation and immune response. IL-6 is secreted by macrophages, dendritic cells and B cells, in response to TNF-α, PGDF and IL-1. The signaling by IL-6 is mediated by heterodimeric receptor, IL-6R, comprising of IL-6Rα (soluble factor) and gp130 (sometimes called IL-6Rβ). gp130 is crucial component for downstream signal transduction. In response to IL-6, gp130 activates kinases of JAK family, STATs, MAPK and Ras proteins. IL-6-mediated signaling is essential for normal development of T and B cells and has been implicated in many diseases such as rheumatoid arthritis, Crohn disease, sepsis, fever, systemic lupus erythematosus, osteoporosis and insulin resistance. Monoclonal Anti-Interleukin-6 antibody recognizes human IL-6. The antibody shows no cross-reactivity with recombinant mouse IL-6 or recombinant human IL-6 sR, OSM, LIF CNTF, or IL-11 or recombinant horse gp130.

Specificity

The antibody will neutralize the biological activity of recombinant human IL-6. The antibody shows no cross-reactivity with recombinant mouse IL-6 or recombinant human IL-6 sR, OSM, LIF CNTF, or IL-11 or recombinant horse gp130.

Immunogen

recombinant human IL-6.

Application

Monoclonal Anti-Interleukin-6 antibody may be used for ELISA at a minimum antibody concentration of 4 μg/ml. For immunoblotting a working antibody concentration of 1-2 μg/ml may be used. The antibody may be used in neutralization assays; ND50 is 0.01-0.15 μg/ml. For neutralization of IL-6 from human peripheral blood mononuclear cells, a concentration of 2.5 μg/ml was used.

Physical form

Lyophilized from 0.2 μm filtered solution in phosphate buffered saline.

Preparation Note

Purified using protein A.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The novel differentiation of human blood mononuclear cells into CD1a-negative dendritic cells is stimulated in the absence of exogenous cytokines by an extract prepared from pinecones
Bradley WG et al
Immunopharmacology, 3, 209-223 (2003)
ZuFu Lu et al.
Stem cells translational medicine, 9(3), 403-415 (2020-01-07)
The induced pluripotent stem cell (iPSC) is a promising cell source for tissue regeneration. However, the therapeutic value of iPSC technology is limited due to the complexity of induction protocols and potential risks of teratoma formation. A trans-differentiation approach employing
Cristiane H Squarize et al.
Neoplasia (New York, N.Y.), 8(9), 733-746 (2006-09-21)
The development of head and neck squamous cell carcinoma (HNSCC) involves the accumulation of genetic and epigenetic alterations in tumor-suppressor proteins, together with the persistent activation of growth-promoting signaling pathways. The activation of epidermal growth factor receptor (EGFR) is a
Siti-Fauziah Hendrayani et al.
Oncotarget, 7(27), 41974-41985 (2016-06-02)
The IL-6/STAT3/NF-κB positive feedback loop links inflammation to cancer and maintains cells at a transformed state. Similarly, cancer-associated myofibroblats remains active even in absence of cancer cells. However, the molecular basis of this sustained active state remains elusive. We have
Mysoon M Al-Ansari et al.
Oncotarget, 9(78), 34681-34690 (2018-11-10)
The ATR protein kinase is a master regulator of the cellular responses to DNA damage and replication stresses. Despite these crucial physiological roles, the implication of ATR in human carcinogenesis remains elusive. We have shown here that the ATR level

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service